Although sulphonylureas, biguanides, insulin sensitizers (thiazolidinediones), and other current drugs are valuable in the treatment of type 2 diabetes mellitus, their use is restricted by cost, limited pharmacokinetic properties, secondary failure rates, and accompanying side effects [28]. The gene discussed is INS; the disease is diabetes mellitus.